Biodexa Pharmaceuticals
BDRX
1 hedge funds and large institutions have $433K invested in Biodexa Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
45% more capital invested
Capital invested by funds: $298K → $433K (+$134K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$627K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAME
Lombard Odier Asset Management (Europe)
London,
United Kingdom
|
-$110K |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$98K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $381K | +$627K | +1 | New |
|
2
Renaissance Technologies
New York
| $35K | – | – | – |
|
3
Morgan Stanley
New York
| $15.5K | – | – | – |
|
|
FDCDDQ
4
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $709 | – | – | – |
|
|
MCC
5
Money Concepts Capital
Palm Beach Gardens,
Florida
| $271 | – | – | – |
|
6
UBS Group
Zurich,
Switzerland
| $123 | – | – | – |
|
7
Group One Trading
Chicago,
Illinois
| $2 | – | – | – |
|
|
CS
8
Credit Suisse
Zurich,
Switzerland
| $1 | – | – | – |
|
|
LOAME
9
Lombard Odier Asset Management (Europe)
London,
United Kingdom
| – | -$110K | – | – |
|
|
LOAMU
10
Lombard Odier Asset Management (USA)
New York
| – | -$98K | – | – |
|
BDRX Hedge Fund Activity: Q4 2022 in Review
1 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q4 2022, worth a combined $433K — up 45% from $298K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BDRX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $627K. The largest seller was Lombard Odier Asset Management (Europe), cutting an estimated $110K.
- 1 institutional investor held Biodexa Pharmaceuticals (BDRX) as of Q4 2022, up from 0 in Q3 2022.
- Funds reported $433K of Biodexa Pharmaceuticals stock for Q4 2022, up 45% quarter-over-quarter.
- 1 fund opened new Biodexa Pharmaceuticals positions in Q4 2022 and 0 closed out, a net change of +1 holder.
- The largest Biodexa Pharmaceuticals buyer in Q4 2022 was Armistice Capital, an estimated $627K added.
- The largest Biodexa Pharmaceuticals seller in Q4 2022 was Lombard Odier Asset Management (Europe), an estimated $110K sold.
Based on aggregated 13F filings for Q4 2022.